GGII - Hempacco files patent application for systems and processes for infusing cigarette filters with flavors and aromatics to enhance the customer experience. The patent application extends to tobacco cigarettes, herb cigarettes, cannabis cigarettes, pre-rolls, and hemp cigarettes, targeting menthol cigarettes and flavored vape smokers while Disrupting Tobacco(TM)

San Diego, California--(Newsfile Corp. - June 2, 2021) - Green Globe International Inc. - Hempacco (OTC Pink: GGII) ("GGII") announced they filed a patent application for systems and processes to infuse cigarette and smokable filters with flavorings and aromatics to enhance the customer experience of cigarettes, and pre-rolls, including cannabis cigarettes, herb cigarettes, tobacco cigarettes and hemp cigarettes.

CBD Hemp Cigarettes 20-pack available atwww.RealStuffSmokables.com To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/7978/86216_

This technology allows GGII to change the customer experience of any type of smokable, pre-roll or cigarette by infusing the filter with flavors, aromas, and other additives.

GGII's Portfolio of Herb and Hemp Cigarettes The new cigarette infusion technology can be combined with existing and future technologies to develop unique products. GGII has also licensed a patent for technology to infuse herbal smoking blends of cannabis cigarettes with terpenoids to alter therapeutic effects of the blends. With this patented technology and the new patent pending technology, GGII hopes to create a portfolio of functional herb and hemp cigarettes with various new combinations of flavors, aromas, and functions.

Licensing the Cigarette Infusion Technology GGII plans to license the cigarette filter infusion technology to tobacco companies and cannabis companies worldwide. For tobacco companies, GGII's mission of Disrupting Tobacco™ helps nicotine cigarettes change to other functional cigarettes, such as CBD, CBG, CBN, and other infusions that present an alternative to tobacco nicotine smokers. For the cannabis industry, GGII anticipates that companies will want to infuse their pre-rolls and marijuana cigarettes with terpenes, flavors and aromas, producing new and exciting cannabis cigarette combinations.

"We've developed this technology with our in-house Research and Development team to change the taste, smell, and the entire customer experience in smokables, including hemp cigarettes," said Sandro Piancone, CEO of GGII. "This new technology will be monetized in three ways: 1. By using it in our existing and future smokables brands; 2. With Joint Ventures in herb cigarettes, hemp cigarettes, and other smokables in developing new brands with other companies; 3. By licensing the technology, for example, for a royalty fee for cannabis companies making cigarettes or pre-rolls," concluded Mr. Piancone.

GGII - Hempacco completed and filed a patent application with the United States Patent and Trademark Office ("USPTO") for their proprietary filter infusion technology for flavoring and scenting filters and changing the customer experience of smokables including hemp cigarettes, tobacco cigarettes, pre-rolls, cannabis cigarettes, herb cigarettes, and spiced cigarettes. GGII's new filter infusion technology will be protected for twenty years in the USA when the patent is approved. With a twenty-year head start, GGII plans to launch a functional smokes and Joint Ventures portfolio for furthering their mission of Disrupting Tobacco™.

"This month the FDA announced their ban of Menthol Cigarettes and Flavored Cigars, menthol cigarettes are already banned in my state of California alongside flavored vapes," said Jorge Olson, Co-Founder and CMO of Hempacco. "Think of this scenario: when a smoker goes to a convenience store and orders a pack of menthol cigarettes or their flavored vapes, the clerk will tell them they're illegal, and the smoker has two choices: they can quit smoking right then and there, or they can ask for a pack of hemp cigarettes in menthol, mango, pineapple, or their favorite flavor," said Jorge Olson.

There are more than 100,000 convenience stores in the USA alone and the global market for menthol cigarettes topped $85.48 Billion dollars in 2020 according to Grand View Research. GGII - Hempacco is developing menthol hemp cigarettes and mint, peppermint, and other flavors with their patent pending filter flavor infusion technology. GGII's filter infusion patent application not only discloses infusing filters with flavoring, but the application also covers infusing filters with aromas for hemp cigarettes, tobacco cigarettes, herb cigarettes, cannabis cigarettes, and others.

CBD Hemp Cigarette Solito single stick 100% biodegradable atwww.RealStuffSmokables.com To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/7978/86216_

About Green Global International Inc. (GGII) - Hempacco, Co. Inc.: Hempacco Co, Inc. is Disrupting Tobacco's™ nearly $1 Trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing consumer goods, including CBG and CBD Hemp cigarettes. The Company owns and licenses intellectual property, has conducted extensive research and development, and is engaged in manufacturing and sales of smokable Hemp brands, including The Real Stuff™ Hemp Smokables. The Hempacco Co., Inc. operating segments include joint-venture private label agreements and sales, Intellectual Property licensing, and the development and sales of in-house brands using patented counter displays as well as six hundred Kiosk vending machines called HempBoxes™.

You can buy CBD Hemp Cigarettes at: https://www.RealStuffSmokables.com Contact us by phone for Investment Opportunities: (775) 473-1201 Hempacco is raising capital; get the investment deck here: https://www.hempaccoinc.com

This news release may include forward-looking statements including opinions, assumptions, estimates, the Company's assessment of future plans and operations, including but not limited to information concerning a potential combination with Hempacco and the timing thereof. When used in this document, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded based on expectations and assumptions made by the Company. Forward-looking statements are subject to a wide range of risks and uncertainties. Although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to regulatory and third party approvals not being obtained in the manner or timing anticipated; the ability to implement corporate strategies; the state of domestic capital markets; the ability to obtain financing; changes in general market conditions; industry conditions and events; and other factors more fully described from time to time in the reports and filings made by the Company with OTC Markets Group, Inc. or the securities regulatory authorities. Except as required by applicable laws, the Company does not undertake any obligation to update or revise any forward-looking statements publicly. We intend that all forward-looking statements be subject to the safe-harbor provisions of relevant securities laws and considered forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86216

BridgeBio Pharma said Monday its Pfizer-rivaling heart disease drug failed in a late-stage test — and BBIO stock crashed to a record low.

Investors in Nio (NYSE: NIO) have been on a roller-coaster ride in 2021, but most of that ride has been downhill. As of the close of trading on Friday, shares of the Chinese electric vehicle (EV) company were down by around 54% from its highest-ever trading price of $66.99 in early January and off by more than 37% year to date. Among other issues, investors are concerned about the rapidly spreading omicron COVID-19 variant and its possible impact on the global economy, ongoing semiconductor chip shortages, increasing U.S. regulatory scrutiny on foreign companies, and fears that a debt default by massive Chinese property developer Evergrande Group might set off a financial crisis in Nio's home market.

Our call of the day says investors have been selling high-beta names too hard, because they're about to enter their biggest month.

Last week, Tesla stock got dinged after The New York Times reported that the National Highway Traffic Safety Administration (NHTSA) was looking into potential risks in the company's software -- specifically, whether allowing drivers to play video games on their central infotainment systems while cars were in motion constituted "design defects posing unreasonable risks to safety." Had NHTSA concluded in the affirmative, the agency could have ordered Tesla to halt sales of its electric cars in the U.S. until the "design defect" was remedied.

The dividends for such stocks are pretty much their only attraction. On the other hand, you can find dividend stocks that are anything but boring and stodgy. Here are three dividend stocks that soared more than 50% in 2021 and are still great buys.

It's hard to find fault with Apple (NASDAQ: AAPL) stock these days. Apple stock is up more than 1,000% over the last decade and has gained nearly 400% over the last three years. Keep reading to see whether you're an Apple bull or bear.

Web 3.0 is widely considered to be the next frontier of internet technology, making the metaverse a golden macrotrend for retail investors. The metaverse refers to an easily scalable real-time virtual reality or mixed reality world, comprising several interoperable, immersive, and interactive 3D environments. The metaverse is also expected to maintain all relevant information about payments, identity, and history across user sessions.

Two blue-chip value stocks, a growth at reasonable price stock, a growth stock with upside potential, and a COVID-19 pandemic play make up a list of five stocks to buy for 2022.

In the meantime, many are generating gushers of cash flow, which they're using to pay big-time dividends. Two lucrative income streams that aren't likely to go away anytime soon are those paid by Kinder Morgan (NYSE: KMI) and Williams Companies (NYSE: WMB). Natural gas pipeline giant Kinder Morgan currently offers a dividend yield of 7%.

ClearBridge Investments, an investment management firm, published its “Small Cap Value Strategy” third quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge Small Cap Value Strategy outperformed the Russell 2000 Value Index, the Strategy’s benchmark, during the third quarter of 2021. You can take a look at the fund’s […]

When you leave a job, and an IRA rollover is only one way to preserve the money’s tax-deferred status, and it's not always the best.

The company, which is sparing its executives from the cut, says it brings benefits in line with what other firms offer. One retiree: ‘If there isn’t a legal obligation, there certainly is a moral obligation.’

Abbott Laboratories (NYSE: ABT) shares have gained around 26% in 2021. Despite the big payout bumps, Abbott only needed around 33% of the free cash flow its operations generated over the past year to make dividend payments. Despite pandemic pressure, medical-device segment sales during the first nine months of 2021 rose 24.5% year over year to $10.6 billion.

The drugmaker says its acoramidis trial for ATTR-CM treatment didn't meet primary endpoints, sending the stock plummeting.

My three stocks to avoid last week were on the move -- as Cintas, Beyond Meat, and GameStop were down 1%, 2%, and 2%, respectively -- averaging out to a 1.7% decline. This week, I see AMC Entertainment (NYSE: AMC), GameStop (NYSE: GME) and Robinhood Markets (NASDAQ: HOOD) as stocks that you may want to consider steering clear from. Last week should've been great for AMC shareholders.

In the last batch, taxpayers got close to $1,200 back, on average.

Since the Great Recession officially ended in 2009, growth stocks have been the driving force on Wall Street. Low lending rates, massive government spending, and the Federal Reserve providing an abundant pool of cheap capital have incentivized businesses to hire, innovate, and acquire other companies. The chickens are now coming home to roost in terms of runaway inflation, and though the Fed has indicated rate hikes are coming to combat high prices, effects won't be felt right away.

There's no denying that 2021 has been a rough year for many biotech stocks. The shares of quite a few big and small biotech companies alike are set to finish the year in negative territory. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Novartis (NYSE: NVS), and Vertex Pharmaceuticals (NASDAQ: VRTX).

These last few weeks of 2021 have seen increased market volatility. Along with Omicron fears, the market fluctuations have come just as Wall Street is digesting the fact of a new Fed policy in the New Year, including the tightening up of monetary policy and at least one, probably more, interest rate hikes. The Fed’s easy money has been supportive for the better part of the past decade or more, and investors are rightly wondering how the market will adapt. Looking ahead, Wedbush’s Daniel Ives is

'Rich Dad Poor Dad' is as bearish as ever.